In vivo studies using mice susceptible to atherosclerosis, with genetic deficient in MCP-1 (CCL2) or its receptor, CCR2, have demonstrated significant protection against lesion formation, possibly by a decreased subendothelial monocyte accumulation [63]. Here, CCL2 is linked to atherosclerosis.